Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Long-Term Follow-Up Result of Hydroxyurea Chemotherapy for Recurrent Meningiomas

  • Kim, Min-Su (Department of Neurosurgery, College of Medicine, Yeungnam University) ;
  • Yu, Dong-Woo (Department of Neurosurgery, College of Medicine, Yeungnam University) ;
  • Jung, Young-Jin (Department of Neurosurgery, College of Medicine, Yeungnam University) ;
  • Kim, Sang Woo (Department of Neurosurgery, College of Medicine, Yeungnam University) ;
  • Chang, Chul-Hoon (Department of Neurosurgery, College of Medicine, Yeungnam University) ;
  • Kim, Oh-Lyong (Department of Neurosurgery, College of Medicine, Yeungnam University)
  • Received : 2012.06.11
  • Accepted : 2012.12.18
  • Published : 2012.12.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : Meningiomas represent 18-20% of all intracranial tumors and have a 20-50% 10-year recurrence rate, despite aggressive surgery and irradiation. Hydroxyurea, an inhibitor of ribonucleotide reductase, is known to inhibit meningioma cells by induction of apoptosis. We report the long-term follow-up result of hydroxyurea therapy in the patients with recurrent meningiomas. Methods : Thirteen patients with recurrent WHO grade I or II meningioma were treated with hydroxyurea (1000 $mg/m^2/day$ orally divided twice per day) from June 1998 to February 2012. Nine female and 4 male, ranging in age from 32 to 83 years (median age 61.7 years), were included. Follow-up assessment included physical examination, computed tomography, and magnetic resonance imaging (MRI). Standard neuro-oncological response criteria (Macdonald criteria) were used to evaluate the follow-up MRI scans. The treatment was continued until there was objective disease progression or onset of unmanageable toxicity. Results : Ten of the 13 patients (76.9%) showed stable disease after treatment, with time to progression ranging from 8 to 128 months (median 72.4 months; 6 patients still accruing time). However, there was no complete response or partial response in any patients. Three patients had progressive disease after 88, 89, 36 months, respectively. There was no severe (Grade III-IV) blood systemic disorders and no episodes of non-hematological side effects. Conclusion : This study showed that hydroxyurea is a modestly active agent against recurrent meningiomas and can induce long-term stabilization of disease in some patients. We think that hydroxyurea treatment is well tolerated and convenient, and could be considered as an alternative treatment option in patients with recurrent meningiomas prior to reoperation or radiotherapy.

Keywords

References

  1. Adegbite AB, Khan MI, Paine KW, Tan LK : The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58 : 51-56, 1983 https://doi.org/10.3171/jns.1983.58.1.0051
  2. Blasberg RG, Patlak C, Fenstermacher JD : Intrathecal chemotherapy : brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195 : 73-83, 1975
  3. Chamberlain MC : Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 84 : 733-736, 1996 https://doi.org/10.3171/jns.1996.84.5.0733
  4. Chamberlain MC, Glantz MJ : Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113 : 2146-2151, 2008 https://doi.org/10.1002/cncr.23803
  5. Chamberlain MC, Glantz MJ, Fadul CE : Recurrent meningioma : salvage therapy with long-acting somatostatin analogue. Neurology 69 : 969-973, 2007 https://doi.org/10.1212/01.wnl.0000271382.62776.b7
  6. Chamberlain MC, Johnston SK : Hydroxyurea for recurrent surgery and radiation refractory meningioma : a retrospective case series. J Neurooncol 104 : 765-771, 2011 https://doi.org/10.1007/s11060-011-0541-5
  7. Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL : Benign meningiomas : primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39 : 427-436, 1997 https://doi.org/10.1016/S0360-3016(97)00317-9
  8. Forbes AR, Goldberg ID : Radiation therapy in the treatment of meningioma : the Joint Center for Radiation Therapy experience 1970 to 1982. J Clin Oncol 2 : 1139-1143, 1984 https://doi.org/10.1200/JCO.1984.2.10.1139
  9. Goldsmith BJ, Wara WM, Wilson CB, Larson DA : Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80 : 195-201, 1994 https://doi.org/10.3171/jns.1994.80.2.0195
  10. Gwilt PR, Tracewell WG : Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 34 : 347-358, 1998 https://doi.org/10.2165/00003088-199834050-00002
  11. Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG : Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma : results of a pilot study. J Neurooncol 74 : 157-165, 2005 https://doi.org/10.1007/s11060-004-2337-3
  12. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, et al. : The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40 : 271-275, 1997 https://doi.org/10.1097/00006123-199702000-00007
  13. Kallio M, Sankila R, Hakulinen T, Jääskeläinen J : Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 31 : 2-12, 1992 https://doi.org/10.1227/00006123-199207000-00002
  14. Kyritsis AP : Chemotherapy for meningiomas. J Neurooncol 29 : 269-272, 1996 https://doi.org/10.1007/BF00165657
  15. Lee JH, Kim OL, Kim SH, Bae JH, Choi BY, Cho SH : Hydroxyurea treatment for unresectable and uecurrent meningiomas. J Korean Neurosurg Soc 30 : S120-S123, 2001
  16. Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT, Koepsell TD : Epidemiology of intracranial meningioma. Cancer 72 : 639-648, 1993 https://doi.org/10.1002/1097-0142(19930801)72:3<639::AID-CNCR2820720304>3.0.CO;2-P
  17. Lori F, Lisziewicz J : Hydroxyurea : overview of clinical data and antiretroviral and immunomodulatory effects. Antivir Ther 4 Suppl 3 : 101-108, 1999
  18. Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, et al. : Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67 : 221-226, 2004 https://doi.org/10.1023/B:NEON.0000021827.85754.8e
  19. Martin DS, Stolfi RL, Colofiore JR : Perspective : the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Cancer Invest 15 : 372-381, 1997 https://doi.org/10.3109/07357909709039742
  20. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE : Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97 : 341-346, 2002 https://doi.org/10.3171/jns.2002.97.2.0341
  21. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ : Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 34 : 817-822, 1996 https://doi.org/10.1016/0360-3016(95)02166-3
  22. Miralbell R, Linggood RM, de la Monte S, Convery K, Munzenrider JE, Mirimanoff RO : The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 13 : 157-164, 1992 https://doi.org/10.1007/BF00172765
  23. Navarra P, Preziosi P : Hydroxyurea : new insights on an old drug. Crit Rev Oncol Hematol 29 : 249-255, 1999 https://doi.org/10.1016/S1040-8428(98)00032-8
  24. Newton HB : Handbook of brain tumor chemotherapy. Amsterdam, Boston : Elsevier Medical Publishers/Academic Press, 2006, ppxvi, pp510-524
  25. Newton HB, Scott SR, Volpi C : Hydroxyurea chemotherapy for meningiomas : enlarged cohort with extended follow-up. Br J Neurosurg 18 : 495-499, 2004 https://doi.org/10.1080/02688690400012392
  26. Newton HB, Slivka MA, Stevens C : Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49 : 165-170, 2000 https://doi.org/10.1023/A:1026770624783
  27. Newton HB, Turowski RC, Stroup TJ, McCoy LK : Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann Pharmacother 33 : 816-832, 1999 https://doi.org/10.1345/aph.18353
  28. Noiri E, Masaki I, Fujino K, Tsuchiya M : Efficacy of a continuous syringe extraction method for monitoring hemodialysis ultrafiltrate. ASAIO J 46 : 461-463, 2000 https://doi.org/10.1097/00002480-200007000-00019
  29. Pollock BE, Stafford SL, Utter A, Giannini C, Schreiner SA : Stereotactic radiosurgery provides equivalent tumor control to Simpson Grade 1 resection for patients with small- to medium-size meningiomas. Int J Radiat Oncol Biol Phys 55 : 1000-1005, 2003 https://doi.org/10.1016/S0360-3016(02)04356-0
  30. Rohringer M, Sutherland GR, Louw DF, Sima AA : Incidence and clinicopathological features of meningioma. J Neurosurg 71 : 665-672, 1989 https://doi.org/10.3171/jns.1989.71.5.0665
  31. Rosenthal MA, Ashley DL, Cher L : Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci 9 : 156-158, 2002 https://doi.org/10.1054/jocn.2001.1019
  32. Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, et al. : Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86 : 845-852, 1997 https://doi.org/10.3171/jns.1997.86.5.0845
  33. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, et al. : Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86 : 840-844, 1997 https://doi.org/10.3171/jns.1997.86.5.0840
  34. Simpson D : The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20 : 22-39, 1957 https://doi.org/10.1136/jnnp.20.1.22
  35. Stearns B, Losee KA, Bernstein J : Hydroxyurea. A new type of potential antitumor agent. J Med Chem 6 : 201, 1963 https://doi.org/10.1021/jm00338a026
  36. Stewart BW : Mechanisms of apoptosis : integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 86 : 1286-1296, 1994 https://doi.org/10.1093/jnci/86.17.1286

Cited by

  1. Current standing and frontiers of gene therapy for meningiomas vol.35, pp.6, 2013, https://doi.org/10.3171/2013.8.focus13305
  2. The importance of microsurgery in childhood meningioma: a case report vol.31, pp.1, 2015, https://doi.org/10.1007/s00381-014-2490-8
  3. Systemic therapy for recurrent meningioma vol.16, pp.8, 2012, https://doi.org/10.1080/14737175.2016.1184087
  4. Medical management of meningioma in the era of precision medicine vol.44, pp.4, 2012, https://doi.org/10.3171/2018.1.focus17754
  5. Medical management of meningioma in the era of precision medicine vol.44, pp.4, 2012, https://doi.org/10.3171/2018.1.focus17754
  6. Role of hydroxyurea as an adjuvant treatment after Gamma knife radiosurgery for atypical (WHO grade II) meningiomas vol.30, pp.2, 2018, https://doi.org/10.1016/j.jnci.2018.04.001
  7. Expression of Cathepsins B, D, and G in WHO Grade I Meningioma vol.6, pp.None, 2012, https://doi.org/10.3389/fsurg.2019.00006
  8. Children’s Cancer and Leukaemia Group (CCLG): review and guidelines for the management of meningioma in children, teenagers and young adults vol.34, pp.2, 2020, https://doi.org/10.1080/02688697.2020.1726286